[Featured Stock] MedPacto Hits Lower Limit Amid Clinical Side Effect News of Immuno-Oncology Drug

[Asia Economy Reporter Ji Yeon-jin] MedPacto recorded a limit-down after news emerged that serious side effects were confirmed in the combination clinical trial of its immuno-oncology drug 'Bactosertib'.

MedPacto is trading at 37,300 KRW, down 29.88% compared to the previous day, since the market opened.

The news that serious side effects were confirmed in the combination clinical trial of the immuno-oncology drug developed by MedPacto appears to have driven the stock price down.

MedPacto is currently conducting a Phase 2 clinical trial combining its developed drug 'Bactosertib' with MSD's immuno-oncology drug 'Keytruda' to treat non-small cell lung cancer patients.

However, there have been reports of deaths due to significant skin toxicity and liver toxicity in the clinical trial, and to address these side effects, MedPacto submitted a plan to the Ministry of Food and Drug Safety to reduce the dosage of Bactosertib in the existing clinical trial, but it was rejected, according to reports.

This content was produced with the assistance of AI translation services.